Deal title Principal company/nonprofit Partner company/nonprofit Value (US$M) Start date

August

Opal Biosciences and ARC Research Hub to conduct study for efficacy of BDM-I against gonorrhea Australian Research Council Opal Biosciences Ltd. Payment unspecified 8/20/19
Emmac and University of Insubria to research on cannabinoids against immune diseases Center of Research in Medical Pharmacology at the Italian University of Insubria Emmac Life Sciences plc Payment unspecified 8/6/19
Central South University and Guangzhou Bebetter Medicine Technology to develop SM-1 against cancer Central South University Guangzhou Bebetter Medicine Technology Co. Ltd. Payment unspecified 8/23/19
Emergent to supply ACAM-2000 to HHS for smallpox preparedness in the U.S. Emergent Biosolutions Inc. U.S. Department of Health and Human Services $2,000.00 8/30/19
University Hospitals of Cleveland to study and optimize therapies to treat pancreatic cancer using Genisphere's 3DNA technology Genisphere LLC University Hospitals Of Cleveland Payment unspecified 8/27/19
GSK to grant technology rights to ChAd3 Ebola vaccine and Marburg virus vaccine to Sabin Vaccine Institute Glaxosmithkline plc Sabin Vaccine Institute Payment unspecified 8/6/19
Moffitt Cancer Center to identify and develop therapeutics against cancer using Kintai's PEM technology H Lee Moffitt Cancer Center and Research Institute Kintai Therapeutics Inc. Payment unspecified 8/27/19
Merck to collaborate with Harvard University for immuno-oncology research to treat cancer Harvard Medical School Merck & Co. Inc. Payment unspecified 8/12/19
Helmholtz Zentrum to design and develop targets based on Phio's RNAi platform for T Cell and natural killer cell adoptive cell therapy for cancer Helmholtz Zentrum Munchen Phio Pharmaceuticals Corp. Payment unspecified 8/15/19
Cancer Research UK to develop Hummingbird's HMBD-001 against cancers Hummingbird Bioscience Pte. Ltd. Cancer Research UK Payment unspecified 8/8/19
Sun Pharmaceutical Industries to obtain license to CSIR-IICT's patents relating to therapeutic compounds active across multiple indications Indian Institute of Chemical Technology Sun Pharmaceutical Industries Ltd. $33.60 8/14/19
IBBR and Integrated Biotherapeutics to advance development of an immunotherapeutic for the treatment of bacterial infection Institute for Bioscience and Biotechnology Research Integrated Biotherapeutics Inc. Payment unspecified 8/14/19
IRCM select IRB for IND Filling with the FDA of American Cryostem's Atcell to treat post-concussion syndrome in retired athletes and military person Institute of Regenerative Cellular Medicine American Cryostem Corp. Payment unspecified 8/22/19
Canon and Kyoto University to collaborate on autologous induced pluripotent stem cells research Kyoto University Canon Inc. Payment unspecified 8/1/19
Tonix and MGH to develop TNX-1500 for organ transplant rejection and autoimmune conditions Massachusetts General Hospital Tonix Pharmaceuticals Holding Corp. Payment unspecified 8/21/19
Boehringer Ingelheim and MD Anderson to conduct collaborative research to advance therapies for various types of cancers, including gastrointestinal and lung MD Anderson Cancer Center Boehringer Ingelheim International GmbH Payment unspecified 8/12/19
Sabin Vaccine Institute and NIAID to develop ChAd3 Ebola and Marburg vaccines National Institute of Allergy and Infectious Diseases Sabin Vaccine Institute Payment unspecified 8/6/19
Osaka University and Funpep to develop IL-23-targeted antibody inducing peptides for immune disorders Osaka University Funpep Co. Ltd. Payment unspecified 8/21/19
UNMCCC to use Personalis' Immunoid Next for evaluating biomarkers of response to Olaparib and Tremelimumab against BRCA-deficient ovarian cancer Personalis Inc. University of New Mexico Comprehensive Cancer Center Payment unspecified 8/7/19
Haihe Biopharma to develop and commercialize SIMM and Jinan University's AXL/FLT3 inhibitor, JND-30134 to treat cancer worldwide Shanghai Institute of Materia Medica of the Chinese Academy of Sciences Haihe Pharmaceuticals Co. Ltd. Payment unspecified 8/19/19
Shinshu and Brightpath to develop BP-2301 against solid tumors Shinshu University Brightpath Biotherapeutics Co. Ltd. Payment unspecified 8/19/19
Merck and the Francis Crick Institute to conduct the research on identifying the targets against motor neuron disease The Francis Crick Institute Merck & Co. Inc. Payment unspecified 8/21/19
Ivy Brain Tumor Center to evaluate Salarius' Seclidemstat against glioblastoma The Ivy Brain Tumor Center Salarius Pharmaceuticals Inc. Payment unspecified 8/26/19
Tufts Medical Center to evaluate the Okyo's oral and nasal Bam8 for the treatment of inflammation and neuropathic pain Tufts Medical Center Okyo Pharma Ltd. Payment unspecified 8/19/19
Machavert Pharmaceuticals to develop University of Colorados's small-molecule RAL GTPase inhibitors for KRAS mutant cancers University of Colorado Machavert Pharmaceuticals Inc. Payment unspecified 8/27/19
Microba and UNSW to discover the links with disease states to develop diagnostics and therapeutics using the microbiome analysis University of New South Wales Microba Payment unspecified 8/23/19
AC Immune and University of Pennsylvania to study pathological mechanisms of TDP-43 misfolding and aggregation in neurodegenerative diseases University of Pennsylvania AC Immune SA Payment unspecified 8/12/19
UTSW to evaluate Spring Bank's small-molecule stimulator of interferon gene antagonist compounds in autoimmune and inflammatory disease models University of Texas Southwestern Medical Center Spring Bank Pharmaceuticals Inc. Payment unspecified 8/6/19
Synthetic Biologics and Washington University to evaluate SYN-004 in allogeneic hematopoietic cell transplant recipients Washington University School of Medicine Synthetic Biologics Inc. $3.20 8/7/19
Tonix to develop WSU's TNX-1600 for post-traumatic stress and central nervous system disorders Wayne State University Tonix Pharmaceuticals Holding Corp. $3.47 8/19/19
Yale University to conduct discovery research of Curevac's mRNA-based therapeutic candidates for pulmonary diseases Yale University Curevac GmbH Payment unspecified 8/13/19

No Comments